Cargando…

Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma

Introduction: Adrenocortical carcinoma (AAC) is a rare and aggressive disease, associated with a poor prognosis. Surgery with complete resection (R0) remains the only curative treatment. However, even after complete resection, most patients present with distant metastatic disease. The aim of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Guiomar, Joana Reis, Silva, Diana Festas, Catarino, Diana Filipa, Moreno, Carolina, Fadiga, Lúcia, Lavrador, Mariana, Vieira, Inês, Araújo, Bárbara, Araújo, Cátia, Caetano, Rui, Figueiredo, Arnaldo, Paiva, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089528/
http://dx.doi.org/10.1210/jendso/bvab048.159
_version_ 1783687060038615040
author Guiomar, Joana Reis
Silva, Diana Festas
Catarino, Diana Filipa
Moreno, Carolina
Fadiga, Lúcia
Lavrador, Mariana
Vieira, Inês
Araújo, Bárbara
Araújo, Cátia
Caetano, Rui
Figueiredo, Arnaldo
Paiva, Isabel
author_facet Guiomar, Joana Reis
Silva, Diana Festas
Catarino, Diana Filipa
Moreno, Carolina
Fadiga, Lúcia
Lavrador, Mariana
Vieira, Inês
Araújo, Bárbara
Araújo, Cátia
Caetano, Rui
Figueiredo, Arnaldo
Paiva, Isabel
author_sort Guiomar, Joana Reis
collection PubMed
description Introduction: Adrenocortical carcinoma (AAC) is a rare and aggressive disease, associated with a poor prognosis. Surgery with complete resection (R0) remains the only curative treatment. However, even after complete resection, most patients present with distant metastatic disease. The aim of this study is to determine clinical and pathological features of metastatic disease in AAC. Materials and methods: Retrospective cohort study in 34 patients with AAC followed in our centre since 1991 until 2019. Selected patients with metastatic disease (n=21) and without metastatic disease (=13). Descriptive and comparative data analyses. Statistics: SPSS®v.23, with the variables: age, sex, clinical signs and symptoms, hormonal activity, imaging and pathological characteristics, surgical procedure, postoperative adjuvant treatments and overall survival. Results: 27 (79%) female and 7 (21%) male patients were included in our study, with a median age of 50 ± 13 years at the time of diagnosis. 21 patients (61,2%) presented with metastatic disease (38% of witch at the time of diagnosis) representing the metastatic disease group. 13 (38,8%) patients had no metastases until the collected data (group without metastatic disease). In the comparative analyses between the two groups, patients with metastatic disease had significantly more laparotomy procedures (71,2% n=15 vs 15,4% n=2; p<0,05), bigger tumours (≥ 12cm) (52,4% n=11 vs 23% n=3; p<0,05) and higher Ki67 (34,18% vs 1%, p<0,05). Postoperatively, the metastatic group had higher LDH (LDH at 6 months) (582 ± 502 vs 181 ± 47; p<0,05) and lower overall survival (months) (22,9 ± 4,69 vs 237,16 ± 44,42; p<0,05). Patients with metastatic disease had more constitutional symptoms (weight loss and asthenia) (33,3% n = 7 vs 15,4% n = 2; p = 0.092) and incomplete surgical recessions (R1/R2) (42,8% n = 9 vs 15,4% n = 2; p=0.18), however, without statistical significance. There were no differences regarding: age, sex, hormonal activity, imaging characteristics and post-surgical medical treatment. Conclusion: In this study, the adrenocortical carcinoma metastasis rate was 61,2% with an overall survival of 23 months in the metastatic group. Laparotomy surgeries, tumour size ≥12cm and higher KI67 are features significantly associated with metastatic disease in adrenocortical carcinoma. Constitutional symptoms and incomplete surgical recessions are more common in metastatic patients, however without statistical significance, in this cohort. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.
format Online
Article
Text
id pubmed-8089528
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80895282021-05-06 Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma Guiomar, Joana Reis Silva, Diana Festas Catarino, Diana Filipa Moreno, Carolina Fadiga, Lúcia Lavrador, Mariana Vieira, Inês Araújo, Bárbara Araújo, Cátia Caetano, Rui Figueiredo, Arnaldo Paiva, Isabel J Endocr Soc Adrenal Introduction: Adrenocortical carcinoma (AAC) is a rare and aggressive disease, associated with a poor prognosis. Surgery with complete resection (R0) remains the only curative treatment. However, even after complete resection, most patients present with distant metastatic disease. The aim of this study is to determine clinical and pathological features of metastatic disease in AAC. Materials and methods: Retrospective cohort study in 34 patients with AAC followed in our centre since 1991 until 2019. Selected patients with metastatic disease (n=21) and without metastatic disease (=13). Descriptive and comparative data analyses. Statistics: SPSS®v.23, with the variables: age, sex, clinical signs and symptoms, hormonal activity, imaging and pathological characteristics, surgical procedure, postoperative adjuvant treatments and overall survival. Results: 27 (79%) female and 7 (21%) male patients were included in our study, with a median age of 50 ± 13 years at the time of diagnosis. 21 patients (61,2%) presented with metastatic disease (38% of witch at the time of diagnosis) representing the metastatic disease group. 13 (38,8%) patients had no metastases until the collected data (group without metastatic disease). In the comparative analyses between the two groups, patients with metastatic disease had significantly more laparotomy procedures (71,2% n=15 vs 15,4% n=2; p<0,05), bigger tumours (≥ 12cm) (52,4% n=11 vs 23% n=3; p<0,05) and higher Ki67 (34,18% vs 1%, p<0,05). Postoperatively, the metastatic group had higher LDH (LDH at 6 months) (582 ± 502 vs 181 ± 47; p<0,05) and lower overall survival (months) (22,9 ± 4,69 vs 237,16 ± 44,42; p<0,05). Patients with metastatic disease had more constitutional symptoms (weight loss and asthenia) (33,3% n = 7 vs 15,4% n = 2; p = 0.092) and incomplete surgical recessions (R1/R2) (42,8% n = 9 vs 15,4% n = 2; p=0.18), however, without statistical significance. There were no differences regarding: age, sex, hormonal activity, imaging characteristics and post-surgical medical treatment. Conclusion: In this study, the adrenocortical carcinoma metastasis rate was 61,2% with an overall survival of 23 months in the metastatic group. Laparotomy surgeries, tumour size ≥12cm and higher KI67 are features significantly associated with metastatic disease in adrenocortical carcinoma. Constitutional symptoms and incomplete surgical recessions are more common in metastatic patients, however without statistical significance, in this cohort. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO. Oxford University Press 2021-05-03 /pmc/articles/PMC8089528/ http://dx.doi.org/10.1210/jendso/bvab048.159 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Adrenal
Guiomar, Joana Reis
Silva, Diana Festas
Catarino, Diana Filipa
Moreno, Carolina
Fadiga, Lúcia
Lavrador, Mariana
Vieira, Inês
Araújo, Bárbara
Araújo, Cátia
Caetano, Rui
Figueiredo, Arnaldo
Paiva, Isabel
Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
title Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
title_full Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
title_fullStr Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
title_full_unstemmed Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
title_short Clinical and Pathological Features of Metastatic Adrenocortical Carcinoma
title_sort clinical and pathological features of metastatic adrenocortical carcinoma
topic Adrenal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089528/
http://dx.doi.org/10.1210/jendso/bvab048.159
work_keys_str_mv AT guiomarjoanareis clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT silvadianafestas clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT catarinodianafilipa clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT morenocarolina clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT fadigalucia clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT lavradormariana clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT vieiraines clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT araujobarbara clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT araujocatia clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT caetanorui clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT figueiredoarnaldo clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma
AT paivaisabel clinicalandpathologicalfeaturesofmetastaticadrenocorticalcarcinoma